Status:
COMPLETED
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Mesothelioma, Malignant
Eligibility:
All Genders
Brief Summary
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mes...
Eligibility Criteria
Inclusion
- Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert
Exclusion
- Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
- Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
Key Trial Info
Start Date :
January 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05324436
Start Date
January 8 2022
End Date
June 30 2023
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Shinjuku-ku, Tokyo, Japan, 162-0822